vs
Purple Innovation, Inc.（PRPL）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
Purple Innovation, Inc.的季度营收约是VERACYTE, INC.的1.0倍（$140.7M vs $140.6M），VERACYTE, INC.净利率更高（29.3% vs -2.3%，领先31.5%），VERACYTE, INC.同比增速更快（18.5% vs 9.1%），VERACYTE, INC.自由现金流更多（$48.8M vs $-7.8M），过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs 8.3%）
Purple Carrot是一家总部位于马萨诸塞州尼达姆市的全植物性餐包品牌，由安迪·莱维特创立，每周为订阅用户提供预制餐品和自制餐包。据《大都会》2022年报道，对比美式标准餐食，该品牌每份餐包的碳排放量可降低72%，主打低碳环保的纯植物饮食方案。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
PRPL vs VCYT — 直观对比
营收规模更大
PRPL
是对方的1.0倍
$140.6M
营收增速更快
VCYT
高出9.5%
9.1%
净利率更高
VCYT
高出31.5%
-2.3%
自由现金流更多
VCYT
多$56.6M
$-7.8M
两年增速更快
VCYT
近两年复合增速
8.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $140.7M | $140.6M |
| 净利润 | $-3.2M | $41.1M |
| 毛利率 | 41.9% | 72.5% |
| 营业利润率 | -1.6% | 26.4% |
| 净利率 | -2.3% | 29.3% |
| 营收同比 | 9.1% | 18.5% |
| 净利润同比 | 62.1% | 704.8% |
| 每股收益（稀释后） | $0.03 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRPLVCYT
| Q4 25 | $140.7M | $140.6M | ||
| Q3 25 | $118.8M | $131.9M | ||
| Q2 25 | $105.1M | $130.2M | ||
| Q1 25 | $104.2M | $114.5M | ||
| Q4 24 | $129.0M | $118.6M | ||
| Q3 24 | $118.6M | $115.9M | ||
| Q2 24 | $120.3M | $114.4M | ||
| Q1 24 | $120.0M | $96.8M |
净利润PRPLVCYT
| Q4 25 | $-3.2M | $41.1M | ||
| Q3 25 | $-11.7M | $19.1M | ||
| Q2 25 | $-17.3M | $-980.0K | ||
| Q1 25 | $-19.1M | $7.0M | ||
| Q4 24 | $-8.5M | $5.1M | ||
| Q3 24 | $-39.2M | $15.2M | ||
| Q2 24 | $27.0K | $5.7M | ||
| Q1 24 | $-50.2M | $-1.9M |
毛利率PRPLVCYT
| Q4 25 | 41.9% | 72.5% | ||
| Q3 25 | 42.8% | 69.2% | ||
| Q2 25 | 35.9% | 69.0% | ||
| Q1 25 | 39.4% | 69.5% | ||
| Q4 24 | 42.9% | 66.4% | ||
| Q3 24 | 29.7% | 68.2% | ||
| Q2 24 | 40.7% | 68.1% | ||
| Q1 24 | 34.8% | 64.5% |
营业利润率PRPLVCYT
| Q4 25 | -1.6% | 26.4% | ||
| Q3 25 | -10.2% | 17.4% | ||
| Q2 25 | -13.5% | -4.0% | ||
| Q1 25 | -13.9% | 2.5% | ||
| Q4 24 | -6.0% | 3.5% | ||
| Q3 24 | -39.5% | 10.4% | ||
| Q2 24 | -12.1% | 4.0% | ||
| Q1 24 | -19.3% | -4.8% |
净利率PRPLVCYT
| Q4 25 | -2.3% | 29.3% | ||
| Q3 25 | -9.9% | 14.5% | ||
| Q2 25 | -16.5% | -0.8% | ||
| Q1 25 | -18.4% | 6.2% | ||
| Q4 24 | -6.6% | 4.3% | ||
| Q3 24 | -33.1% | 13.1% | ||
| Q2 24 | 0.0% | 5.0% | ||
| Q1 24 | -41.8% | -1.9% |
每股收益（稀释后）PRPLVCYT
| Q4 25 | $0.03 | $0.50 | ||
| Q3 25 | $0.11 | $0.24 | ||
| Q2 25 | $0.16 | $-0.01 | ||
| Q1 25 | $0.18 | $0.09 | ||
| Q4 24 | $0.08 | $0.07 | ||
| Q3 24 | $0.36 | $0.19 | ||
| Q2 24 | $0.00 | $0.07 | ||
| Q1 24 | $0.47 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $24.3M | $362.6M |
| 总债务越低越好 | $126.7M | — |
| 股东权益账面价值 | $-29.7M | $1.3B |
| 总资产 | $296.3M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRPLVCYT
| Q4 25 | $24.3M | $362.6M | ||
| Q3 25 | $32.4M | $315.6M | ||
| Q2 25 | $34.2M | $219.5M | ||
| Q1 25 | $21.6M | $186.1M | ||
| Q4 24 | $29.0M | $239.1M | ||
| Q3 24 | $23.4M | $274.1M | ||
| Q2 24 | $23.4M | $235.9M | ||
| Q1 24 | $34.5M | $209.2M |
总债务PRPLVCYT
| Q4 25 | $126.7M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $70.7M | — | ||
| Q3 24 | $50.8M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PRPLVCYT
| Q4 25 | $-29.7M | $1.3B | ||
| Q3 25 | $-26.9M | $1.3B | ||
| Q2 25 | $-15.6M | $1.2B | ||
| Q1 25 | $1.3M | $1.2B | ||
| Q4 24 | $20.2M | $1.2B | ||
| Q3 24 | $28.0M | $1.2B | ||
| Q2 24 | $66.4M | $1.1B | ||
| Q1 24 | $65.5M | $1.1B |
总资产PRPLVCYT
| Q4 25 | $296.3M | $1.4B | ||
| Q3 25 | $302.1M | $1.4B | ||
| Q2 25 | $303.8M | $1.3B | ||
| Q1 25 | $293.8M | $1.3B | ||
| Q4 24 | $307.8M | $1.3B | ||
| Q3 24 | $309.3M | $1.3B | ||
| Q2 24 | $362.1M | $1.2B | ||
| Q1 24 | $382.1M | $1.2B |
负债/权益比PRPLVCYT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.50× | — | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.8M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $-7.8M | $48.8M |
| 自由现金流率自由现金流/营收 | -5.5% | 34.7% |
| 资本支出强度资本支出/营收 | 1.4% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $-41.9M | $126.6M |
8季度趋势，按日历期对齐
经营现金流PRPLVCYT
| Q4 25 | $-5.8M | $52.6M | ||
| Q3 25 | $-968.0K | $44.8M | ||
| Q2 25 | $-4.0M | $33.6M | ||
| Q1 25 | $-23.1M | $5.4M | ||
| Q4 24 | $6.8M | $24.5M | ||
| Q3 24 | $1.1M | $30.0M | ||
| Q2 24 | $-8.9M | $29.6M | ||
| Q1 24 | $-16.8M | $-9.0M |
自由现金流PRPLVCYT
| Q4 25 | $-7.8M | $48.8M | ||
| Q3 25 | $-1.8M | $42.0M | ||
| Q2 25 | $-7.0M | $32.3M | ||
| Q1 25 | $-25.3M | $3.5M | ||
| Q4 24 | $5.7M | $20.4M | ||
| Q3 24 | $101.0K | $27.7M | ||
| Q2 24 | $-11.0M | $26.8M | ||
| Q1 24 | $-19.9M | $-11.1M |
自由现金流率PRPLVCYT
| Q4 25 | -5.5% | 34.7% | ||
| Q3 25 | -1.5% | 31.8% | ||
| Q2 25 | -6.6% | 24.8% | ||
| Q1 25 | -24.3% | 3.1% | ||
| Q4 24 | 4.4% | 17.2% | ||
| Q3 24 | 0.1% | 23.9% | ||
| Q2 24 | -9.2% | 23.4% | ||
| Q1 24 | -16.5% | -11.5% |
资本支出强度PRPLVCYT
| Q4 25 | 1.4% | 2.7% | ||
| Q3 25 | 0.7% | 2.1% | ||
| Q2 25 | 2.8% | 1.0% | ||
| Q1 25 | 2.2% | 1.6% | ||
| Q4 24 | 0.8% | 3.5% | ||
| Q3 24 | 0.9% | 1.9% | ||
| Q2 24 | 1.7% | 2.4% | ||
| Q1 24 | 2.5% | 2.2% |
现金转化率PRPLVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | -330.22× | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
